Mohamed Hbibi

Mohamed Hbibi

Auto-generated profile, based on publicly available information

Mohamed Hbibi

Department of Pediatric Hematology-Oncology, CHU Hassan II, Fez, Morocco

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024
Verified
Preprint
Open access
PDF file
MHMohamed Hbibi
Mohamed Hbibi
SBSara Benmiloud
Sara Benmiloud
AKAmina Kili
Amina Kili
NKNisrine Khoubila
Nisrine Khoubila
JEJamila Elhoudzi
Jamila Elhoudzi
LHLaila Hessissen
Laila Hessissen
Background: Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. It represents 2.5% of childhood cancers. Survival has been completely changed thanks to early diagnosis and modern treatment combining chemotherapy and surgery, resulting in survival rates of over 70%. However, a paucity of studies on the pattern of its occurrence in LMIC such as Morocco. The objective of this study is to analyze the epidemiological, clinical, histological and therapeutic profile in Moroccan children with osteosarcoma. Methods: We retrospectively studied 91 patients of osteosarcoma collected from 2013 to 2016 at the four pediatric oncology units in Morocco which treat bone tumors (CHU of Fez, Casablanca, Rabat, Marrakech). Results: Osteosarcoma accounted for 3% of all patients treated for cancer during this period. All patients are histologically proven osteosarcoma. The male/female ratio was 0.85 with a mean age at diagnosis of 13 years. Swelling and pain were the main symptom. The most frequent location of involvement was the knee. Among the 91 patients, 40 patients didn’t have metastasis, while 40 had metastasis (pulmonary, bone). For 11 patients, they didn’t be evaluated for distant spread of cancer. The treatment options were chemotherapy and surgery. The evolution was marked by 31% of deaths, 36% of abandonment , 9% of lost to follow-up, while only 20% of complete remission and 4% alive under palliative treatment and. The 3-year survival study was 50%. Conclusion: The alarming data obtained prompt a review of the management process for patients in all stage of care pathways.

28 February 2022 in Journal of Clinical Images and Medical Case Reports
Verified
Journal Article
Open access
SBSanaa Bouramdane
Sanaa Bouramdane
SBSarra Benmiloud
Sarra Benmiloud
MHMohamed Hbibi
Mohamed Hbibi
MOMariam B Oubbou
Mariam B Oubbou
YBYoussef Bouabdellah
Youssef Bouabdellah
MHMustapha Hida
Mustapha Hida

9 October 2026 in Pan African Medical Journal
Verified
Journal Article
Open access
MHMohamed Hbibi
Mohamed Hbibi
ZKZakaria Kasmi
Zakaria Kasmi
FAFatima Ailal
Fatima Ailal
MIMounia Lakhdar Idrissi
Mounia Lakhdar Idrissi
MHMoustapha Hida
Moustapha Hida
ABAhmed Aziz Bousfiha
Ahmed Aziz Bousfiha
Primary immune regulatory disorders (PIRDs) are a clinically and genetically complex subgroup of inborn errors of immunity. They are characterized by defects in the mechanisms controlling immune tolerance and inflammatory responses. Loss- or gain-of-function mutations can lead to impaired immune tolerance or exaggerated immune activation, resulting in a broad spectrum of phenotypes that include recurrent infections, lymphoproliferation, autoinflammation, and refractory autoimmunity, particularly autoimmune cytopenias. Through two illustrative pediatric cases, we highlight the diagnostic challenges faced when managing children with unexplained autoimmune cytopenias. In both patients, an initial presentation with autoimmune cytopenia ultimately led, after significant diagnostic delays, to the identification of distinct underlying PIRDs: autoimmune lymphoproliferative syndrome (ALPS) in one case and lipopolysaccharide-responsive beige-like anchor protein (LRBA) deficiency in the other. These cases underscore the importance of early recognition and comprehensive immunological evaluation to facilitate timely genetic diagnosis and guide targeted therapeutic strategies.